HWM
NBIX icon

Hemington Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Hemington Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$13K Buy
96
+10
+12% +$1.35K ﹤0.01% 787
2025
Q2 		$10K Buy
86
+41
+91% +$4.7K ﹤0.01% 866
2025
Q1 		$4K Buy
45
+1
+2% +$127 ﹤0.01% 1127
2024
Q4 		$6K Buy
44
+12
+38% +$1.48K ﹤0.01% 961
2024
Q3 		$3K Buy
+32
New +$4.39K ﹤0.01% 1089

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hemington Wealth Management's NBIX Position: Q3 2025 in Review

Hemington Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 12% in Q3 2025, buying an estimated $1.35K and bringing the position to 96 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #787.

Hemington Wealth Management first reported a position in NBIX in Q3 2024 and has held it in 5 quarters since. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Hemington Wealth Management held 96 shares of Neurocrine Biosciences worth $13K as of Q3 2025.
  • Hemington Wealth Management bought 10 Neurocrine Biosciences shares in Q3 2025, an estimated $1.35K.
  • Neurocrine Biosciences made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #787 holding.
  • Hemington Wealth Management first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 5 quarters since.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.